Analysed VIR BIOTECHNOLOGY INC (VIR:NASDAQ) News Sources
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
05-10-2026
yahoo.com
How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment Narrative
08-10-2026
yahoo.com
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
08-10-2026
yahoo.com
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
14-10-2026
yahoo.com
Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors
14-10-2026
yahoo.com
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
15-10-2026
pharmaceutical-technology.com
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts
16-10-2026
stocktwits.com
What is the current price of VIR BIOTECHNOLOGY INC (VIR:NASDAQ)?
The current price of VIR BIOTECHNOLOGY INC (VIR:NASDAQ) is $11.64.
VIR BIOTECHNOLOGY INC (VIR:NASDAQ) absolute price change since previous trading day?
The absolute price change of VIR BIOTECHNOLOGY INC (VIR:NASDAQ) since the previous trading day is $0.6.
VIR BIOTECHNOLOGY INC (VIR:NASDAQ) percentage price change since previous trading day?
The percentage price change of VIR BIOTECHNOLOGY INC (VIR:NASDAQ) since the previous trading day is 5.4348%.
What is the most recent average sentiment score for VIR BIOTECHNOLOGY INC (VIR:NASDAQ)?
The most recent average sentiment score for VIR BIOTECHNOLOGY INC (VIR:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for VIR BIOTECHNOLOGY INC (VIR:NASDAQ)?
The most recent sentiment for VIR BIOTECHNOLOGY INC (VIR:NASDAQ) is .
SEC-8K** Filing Available For VIR BIOTECHNOLOGY INC (VIR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.